反应详情

The title compound was prepared by substituting N-(tert-butoxycarbonyl)-N-methyl-L-norvaline for (S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid and (3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-amine from Example 262 Step B for (3aR,4S,6aS)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-amine in the procedure described in Example 587: 1H NMR (400 MHz, pyridine-d5) δ ppm 8.67-8.57 (m, 1H), 8.30 (d, J=7.4, 1H), 7.68 (dd, J=8.9, 2.4, 1H), 6.40 (d, J=8.9, 1H), 4.48-4.37 (m, 1H), 3.87-3.78 (m, 1H), 3.67 (dd, J=11.1, 7.4, 1H), 3.59 (dd, J=10.7, 8.1, 1H), 3.37-3.29 (m, 1H), 3.20 (dd, J=6.9, 6.2, 1H), 2.82-2.67 (m, 2H), 2.43 (s, 3H), 2.16 (dtd, J=12.4, 7.2, 4.9, 1H), 2.00-1.90 (m, 1H), 1.83 (ddt, J=12.8, 9.5, 6.3, 1H), 1.76-1.64 (m, 2H), 1.60-1.35 (m, 4H), 0.86 (t, J=7.3, 3H); MS (ESI+) m/z 385 (M+H)+.